Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients with advanced cancer frequently experience anorexia and cachexia, which are associated with reduced food intake, altered body composition, and decreased functionality. We assessed anamorelin, a novel ghrelin-receptor agonist, on cachexia in patients with advanced non-small-cell lung cancer and cachexia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Apr 2016

Volume: 17

Issue: 4

Affiliations

[1 ] Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: jtemel@partners.org.

[2 ] Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

[3 ] Department of Palliative and Supportive Care, Flinders University, Adelaide, SA, Australia.

[4 ] Helsinn Therapeutics (US) Incorporated, Iselin, NJ, USA.

[5 ] Department of Surgery, Royal Infirmary, Edinburgh, UK.

Article

Publisher Item ID: S1470-2045(15)00558-6

DOI: 10.1016/S1470-2045(15)00558-6

PubMed ID: 26906526

SO-VID: fc29bdd3-0519-41b7-b4cd-84be3e36353d

History

Data availability:

Comments

Comment on this article

scite_

Cited by 201

See all cited by

- Version 1